Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice.


Journal

ImmunoHorizons
ISSN: 2573-7732
Titre abrégé: Immunohorizons
Pays: United States
ID NLM: 101708159

Informations de publication

Date de publication:
15 06 2021
Historique:
received: 26 04 2021
accepted: 26 04 2021
entrez: 16 6 2021
pubmed: 17 6 2021
medline: 1 2 2022
Statut: epublish

Résumé

Although CD14 has been implicated in the initiation of multiple TLR-mediated inflammatory responses to sepsis and sepsis-related acute lung injury (ALI), an inhibitor of CD14, except for neutralizing Abs, has not been developed. A partial peptide, microglial healing peptide 1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN), derived from the receptor activator of the NF-кB ligand, was recently found to inhibit multiple TLR signaling in the macrophages. Therefore, we hypothesized that the inhibitory effect of MHP1-AcN might be through the inhibition of CD14, a common coreceptor for multiple TLRs. In cultured mouse macrophages, MHP1-AcN was shown to bind to CD14 and compete with LPS for competitive inhibition of CD14, resulting in inhibition of TLR4 signaling, including NF-кB and IFN regulatory factor 3 activation and nuclear translocation. In addition to TLR2, TLR4, and TLR7, MHP1-AcN also inhibited TLR3 signaling and

Identifiants

pubmed: 34131020
pii: immunohorizons.2000112
doi: 10.4049/immunohorizons.2000112
doi:

Substances chimiques

Cd14 protein, mouse 0
Lipopolysaccharide Receptors 0
Lipopolysaccharides 0
Peptides 0
RANK Ligand 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

438-447

Informations de copyright

Copyright © 2021 The Authors.

Auteurs

Nan Ju (N)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Geriatric of General Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Hiroki Hayashi (H)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Munehisa Shimamura (M)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; nakagami@gts.med.osaka-u.ac.jp shimamuu@cgt.med.osaka-u.ac.jp.
Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Japan; and.

Shota Yoshida (S)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Geriatric of General Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Ryo Nakamaru (R)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Department of Geriatric of General Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Hironori Nakagami (H)

Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; nakagami@gts.med.osaka-u.ac.jp shimamuu@cgt.med.osaka-u.ac.jp.

Ryuichi Morishita (R)

Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Japan.

Hiromi Rakugi (H)

Department of Geriatric of General Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH